Clover Biopharmaceuticals has established a commercial collaboration with Keyuan Xinhai (Beijing) Medical Products Trading (Kyuan Trade) for the launch of its quadrivalent seasonal influenza vaccine, AdimFlu-S (QIS), in China.
The China National Medical Products Administration approved AdimFlu-S (QIS) in January 2022 for individuals aged three years and above.
Go deeper with GlobalData
The vaccine contains haemagglutinin from four influenza virus strains, two A and two B.
This increases the vaccine’s chance of high effectiveness against seasonal influenza compared to trivalent options.
Clover Biopharmaceuticals will use Kyuan Trade’s extensive sales and distribution network to complement its in-house capabilities and increase access to its AdimFlu-S (QIS) across the country.
Clover Biopharmaceuticals CEO and executive director Joshua Liang stated: “We are thrilled to partner with Kyuan Trade, which has a large and talented commercial team, a broad distribution network that extends across 31 provinces, municipalities and autonomous regions, and an excellent modern logistics network.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“With the seasonal influenza market in China poised for continued growth, this partnership is expected to help accelerate our commercial success and near-term revenue potential.”
The Chinese market for the seasonal influenza vaccine has been growing by 30% per year.
Clover Biopharmaceuticals expects to launch the influenza vaccine in the second half of 2023.
